8-K: Krystal Biotech Reports Strong 2023 Results and Advances Pipeline

Krystal Biotech announced positive financial results for 2023, driven by the commercial launch of VYJUVEK, and provided updates on its clinical pipeline.

Summary

• Krystal Biotech reported $42.1 million in net product revenue for the fourth quarter of 2023 and $50.7 million for the full year, primarily from sales of VYJUVEK.
• The company achieved a gross margin of 93% for the fourth quarter.
• As of February 2024, Krystal Biotech had secured 35% of the identified patient base for VYJUVEK and 228 reimbursement approvals.
• Patient compliance with VYJUVEK treatment was 96% at the end of December 2023.
• The company closed the year with $594.1 million in cash and investments.
• Krystal Biotech is advancing multiple clinical programs, including KB407 for cystic fibrosis, KB408 for alpha-1 antitrypsin deficiency, and KB707 for solid tumors.
• The company anticipates a decision on its European Marketing Authorization Application for B-VEC in the second half of 2024 and plans to file a New Drug Application in Japan in the same period.
• Krystal Biotech reported a net income of $8.7 million for the fourth quarter and $10.9 million for the full year 2023, compared to a net loss in 2022.
• The company expects non-GAAP combined R&D and SG&A expenses to be between $150 million and $175 million for 2024.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to strong financial results, successful product launch, and advancements in the clinical pipeline. The company's strong cash position and regulatory progress further support this positive outlook.

Positives

• The commercial launch of VYJUVEK has been successful, generating significant revenue.
• The company has a strong cash position of $594.1 million.
• Patient compliance with VYJUVEK treatment is very high at 96%.
• The company is making progress in its clinical pipeline with multiple programs advancing.
• Krystal Biotech has secured key regulatory designations, including Orphan Drug Designation in Japan and Fast Track Designation from the FDA.
• The company has achieved positive access for 97% of lives covered under commercial plans and 88% of lives covered under Medicaid for VYJUVEK.
• The company has secured a permanent J-code for VYJUVEK, facilitating reimbursement.
• The company has achieved profitability for both the quarter and the full year 2023.

Negatives

• Selling, general and administrative expenses were $98.4 million for the year, a significant increase compared to the previous year.
• Research and development expenses were $46.4 million for the year, also an increase compared to the previous year.
• The company is still reliant on VYJUVEK for revenue, with other products still in development.

Risks

• The company's future success depends on the continued commercial success of VYJUVEK.
• Regulatory approvals for other products are not guaranteed.
• Clinical trials may not be successful.
• The company may need to raise additional capital in the future.
• The company faces competition from other biotechnology companies.
• The company's forward-looking statements are subject to various risks and uncertainties.

Future Outlook

The company anticipates expanding VYJUVEK access, advancing its clinical pipeline, and reinforcing its leadership in redosable gene therapy. They expect a decision on the European MAA for B-VEC in 2H 2024, plan to file a Japanese NDA for B-VEC in 2H 2024, and expect to announce interim data from the KB408 Phase 1 study in 2H 2024. They also plan to initiate a study of B-VEC eyedrops in 2H 2024 and expect to dose the first patient in the inhaled KB707 Phase 1 study in 1H 2024.

Management Comments

• 2023 was an inflection point for Krystal with the approval and launch of VYJUVEK, the first-ever FDA approved therapy for dystrophic epidermolysis bullosa and only medicine that delivers the corrective power of gene therapy in an easy-to-apply, redosable, topical gel formulation that can be administered at home, said Krish S. Krishnan, Chairman and CEO of Krystal Biotech.
• Our U.S. commercial launch trajectory is tracking closely to that of the best recent rare disease launches with $50.7 million in net product revenue only six months since approval, supported by high patient and physician demand, broad access, and high compliance.

Industry Context

This announcement highlights Krystal Biotech's progress in the gene therapy space, particularly in rare diseases. The successful launch of VYJUVEK positions them as a leader in this area, and the advancement of their pipeline suggests continued growth potential. The company's focus on redosable gene therapy is a key differentiator in the market.

Comparison to Industry Standards

• The $50.7 million in net product revenue for VYJUVEK in its first six months post-approval is a strong performance, comparable to other successful rare disease drug launches such as BioMarin's Vimizim and Sarepta Therapeutics' Exondys 51.
• The 93% gross margin for VYJUVEK is very high, indicating strong pricing power and efficient manufacturing, which is comparable to other high-value gene therapies.
• The company's cash position of $594.1 million is robust, providing a solid foundation for continued research and development, which is similar to other well-funded biotech companies in the clinical stage.
• The company's progress in securing regulatory designations such as Orphan Drug Designation and Fast Track Designation is consistent with industry best practices for developing therapies for rare diseases.

Stakeholder Impact

• Shareholders will likely view the financial results and pipeline progress positively.
• Patients with DEB will benefit from the continued availability and expansion of VYJUVEK.
• Employees may be encouraged by the company's success and growth.
• The company's suppliers and partners may see increased business opportunities.

Next Steps

• The company plans to expand VYJUVEK access in the U.S. and globally.
• The company anticipates a decision on its European Marketing Authorization Application for B-VEC in the second half of 2024.
• The company intends to file a Japanese New Drug Application for B-VEC in the second half of 2024.
• The company plans to announce interim data from its Phase 1 study of KB408 in the second half of 2024.
• The company plans to initiate a study in the second half of 2024 of B-VEC eyedrops for the treatment of lesions in the eye of DEB patients.
• The company expects to dose the first patient with inhaled KB707 for the treatment of patients with locally advanced or metastatic solid tumors of the lung in its Phase 1 clinical study in the first half of 2024.
• Jeune Aesthetics plans to announce results in the first half of 2024 of Cohort 4 of its Phase 1 clinical study to evaluate KB301 for the improvement of dynamic wrinkles of the dcollet and Cohort 3 to evaluate KB301 for the improvement of lateral canthal lines at rest.

Key Dates

Keywords

VYJUVEK, gene therapy, dystrophic epidermolysis bullosa, DEB, B-VEC, KB407, cystic fibrosis, KB408, alpha-1 antitrypsin deficiency, AATD, KB707, solid tumors, clinical trials, FDA, Orphan Drug Designation, Fast Track Designation, revenue, biotechnology